Accredo Health Group, a subsidiary of Medco, won a five-yearcontract as the sole specialty pharmacy for Flolan (epoprostenolsodium, Myogen) for pulmonary arterial hypertension (PAH). Terms ofthe deal were not announced.
Atogepant Shows Superiority Over Topiramate for Migraine Prevention
Topline results from a phase 3 trial showed 64.1% of patients on atogepant achieved a 50% or greater reduction in mean monthly migraine days during months 4 to 6.
The Potential Impact Pharmaceutical Tariffs May Have on Pharmacies
Marta Wosinska, PhD, and Joey Mattingly, PharmD, MBA, PhD, joined Drug Topics to help us understand how pharmaceutical tariffs could potentially impact the pharmacy industry.
Sleep Habits Could Influence Risk of Type 2 Diabetes
Investigators also found that a change in brain functional network connectivity could also be associated with type 2 diabetes risk.
Scripted for Her: Addressing Preconception Health Through MTM
In this episode, Natalie DiPietro Mager, PharmD, PhD speaks with David Bright, PharmD, MBA, professor at Ferris State University College of Pharmacy.
Hair Loss Therapy Shows Potential for Regeneration in Phase 2 Trial
PP405 targets the primary biological pathway that controls the natural hair growth cycle, separating it from existing therapies.
Pneumococcus Remains Significant Cause of Adult Mortality, Morbidity
Researchers conducted a review that provided updated evidence regarding the pneumococcal disease burden, the evolution of pneumococcal vaccines, and the latest immunization strategies.